Les cancers en France-Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1-Tumeurs solides, Juillet, 2013. ,
Incidence and mortality of urological cancers in 2012 in France, Prog Urol, vol.23, pp.57-65, 2013. ,
Survie des personnes atteintes de cancer en France métropolitaine 1989-2013. Institut National Du Cancer, 2016. ,
EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary, Eur J Cancer, vol.45, issue.6, pp.931-91, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00492650
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, vol.349, issue.9, p.1880, 2003. ,
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy, Cancer, vol.115, pp.4104-4109, 2009. ,
Survie attendue des patients atteints de cancers en France: états des lieux, 2010. ,
Prévention et Epidémiologie des Tumeurs en Région Ile-de-France), vol.73, p.p, 1994. ,
, Cancer Statistics Review, 1975.
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J. Clin. Oncol, vol.19, pp.666-675, 2001. ,
Metastases from urothelial carcinoma: role of chemotherapy, Progrès en Urologie, pp.261-276, 2008. ,
Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?, World J Urol, vol.24, p.557, 2006. ,
Patterns of initial transitional cell recurrence in patients after cystectomy, J Urol, vol.175, pp.2054-2061, 2006. ,
Association between smoking and risk of bladder cancer among men and women, JAMA, vol.306, pp.737-782, 2011. ,
Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians, Mutat Res, vol.581, pp.97-104, 2005. ,
Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies, Int J Cancer, vol.86, pp.289-94, 2000. ,
Heavy cigarette smoking and agressive bladder cancer at initial presentation, Urology, vol.86, issue.5, pp.968-72, 2015. ,
Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer, BJU Int, vol.109, pp.70-76, 2012. ,
Effets sur la santé ,
Société française de médecine du travail. Surveillance médico-professionnelle des travailleurs exposés ou ayant été exposés à des agents cancérogènes chimiques : application aux cancérogènes pour la vessie, 2012. ,
The characteristics of bladder cancer after radiotherapy for prostate cancer, Urol Oncol, vol.31, pp.1628-1662, 2013. ,
Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality, World J Urol, vol.35, pp.713-720, 2017. ,
Urologic and male genital manifestations of granulomatosis with polyangiitis, Autoimmunity Reviews, vol.14, pp.897-902, 2015. ,
Urinary schistosomiasis and Cancer, Bull Soc Pathol Exot, vol.110, pp.68-75, 2017. ,
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours, European Urology, vol.70, pp.106-119, 2016. ,
Recommandations françaises du Comité de Cancérologie de l'AFU-Actualisation 2018-2020 :Tumeurs de la vessie, Progrès en Urologie, vol.28, pp.46-78, 2018. ,
, TNM classification of malignant tumours, 2009.
Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers, Eur Urol, vol.73, pp.560-569, 2018. ,
, Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, vol.507, pp.315-322, 2014.
A molecular taxonomy for urothelial carcinoma, Clin Cancer Res, vol.18, pp.3377-3386, 2012. ,
Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification, J Pathol, vol.242, pp.113-138, 2017. ,
Bladder cancer, Nat Rev Dis Primers, vol.3, p.17022, 2017. ,
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, pp.40-48, 2014. ,
Current evidence for transurethral en bloc resection of non-muscle-invasive bladder cancer, Minim Invasive Ther Allied Technol, vol.23, pp.206-219, 2014. ,
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscleinvasive bladder cancer: a critical review of the current literature, Eur Urol, vol.64, pp.624-662, 2013. ,
Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour, BJU Int, vol.99, pp.1363-70, 2007. ,
Evaluation of computed tomography for lymph node staging in bladder cancer prior to radical cystectomy, Urol Int, vol.96, pp.51-57, 2016. ,
The role of computerized tomography in the assessment of perivesical invasion in bladder cancer, Pol J Radiol, vol.81, pp.281-288, 2016. ,
Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder, AJR Am J Roentgenol, vol.180, p.1045, 2003. ,
Preoperative Imaging for Staging Bladder Cancer, Curr Urol Rep, vol.16, p.22, 2015. ,
The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis, Am J Roentgenol, vol.210, pp.95-109, 2018. ,
ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle invasive urothelial carcinoma of the bladder, Eur Urol, vol.63, pp.45-57, 2013. ,
The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer, Eur Urol, vol.55, pp.826-861, 2009. ,
, Advanced Bladder Cancer Meta-Analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data, Eur Urol, vol.48, pp.202-206, 2005.
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis, Oncologist, vol.21, pp.708-723, 2016. ,
Randomized phase III trial of highdoseintensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924, J Clin Oncol, vol.19, pp.2638-2646, 2001. ,
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates, J Clin Oncol, vol.32, pp.1889-1894, 2014. ,
Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement, J Clin Oncol, vol.34, pp.2627-2662, 2016. ,
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial, Ann Oncol, vol.23, pp.695-700, 2012. ,
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial, Lancet Oncol, vol.16, pp.76-86, 2015. ,
Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer, J Clin Oncol, vol.34, pp.825-857, 2016. ,
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials, Eur Urol, vol.66, pp.42-54, 2014. ,
Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline, J Clin Oncol, vol.34, pp.1945-1952, 2016. ,
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, vol.14, pp.2901-2908, 1996. ,
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, vol.366, pp.1477-88, 2012. ,
Radiothérapie des cancers de vessie, Cancer Radiother, vol.20, pp.196-199, 2016. ,
A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer, Urol Oncol, vol.36, pp.43-53, 2018. ,
Longterm survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, Clin Oncol, vol.17, pp.3173-81, 1999. ,
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, vol.18, pp.3068-77, 2000. ,
Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy, J Clin Oncol, vol.29, pp.2432-2470, 2011. ,
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: Phase II-Results of EORTC study 30986, J Clin Oncol, vol.27, pp.5634-5673, 2009. ,
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens, J Clin Oncol, vol.28, pp.1850-55, 2010. ,
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract, J Clin Oncol, vol.27, issue.27, pp.4454-61, 2009. ,
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer, J Clin Oncol, vol.20, pp.937-977, 2002. ,
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy, Int J Clin Oncol, vol.13, pp.510-524, 2008. ,
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma, J Clin Oncol, vol.15, pp.1853-1860, 1997. ,
Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, vol.376, pp.1015-1041, 2017. ,
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial, Lancet, vol.391, pp.748-757, 2018. ,
Principe et technique de la tomographie par émission de positons (TEP), Encycl Med Chir (Editions Scientifiques et Médicales Elsevier SAS, pp.1-22, 2002. ,
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, vol.35, pp.1773-82, 1999. ,
From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, pp.122-50, 2009. ,
Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer, J Clin Oncol. Sept, vol.28, issue.25, pp.3973-3981, 2010. ,
Impact of 18 Fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle: FDG-PET/CT in carcinoma invading bladder muscle, BJU Int, vol.112, issue.6, pp.729-763, 2013. ,
18 F]Fluorodeoxyglucose -positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy, Scand J Urol, vol.49, issue.4, pp.296-301, 2015. ,
Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer, Int J Urol, vol.19, issue.7, pp.639-683, 2012. ,
18F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Aids Staging and Predicts Mortality in Patients with Muscle-invasive Bladder Cancer, Urology, vol.83, issue.2, pp.393-402, 2014. ,
18 Fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study: PET scan for bladder cancer, Int J Urol, vol.20, issue.8, pp.788-96, 2013. ,
Prospective Study of [ 18 F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma, J Clin Oncol, vol.27, issue.26, pp.4314-4334, 2009. ,
Integrated analysis of 18 F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer, European radiology ,
Diagnostic accuracy of F-18 FDG PET/ CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis, Oncology, vol.95, pp.31-38, 2018. ,
FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder Cancer, J Urol, vol.189, issue.5, pp.1687-91, 2013. ,
FDG-PET/CT for assessing the response to Neoadjuvant Chemotherapy in Bladder cancer patients, Clin Genitourin Cancer, vol.16, issue.5, pp.360-364, 2018. ,
Updated 2016 EAU Guidelines on Muscle invasive and Metastatic Bladder Cancer, Eur Urol, vol.71, pp.462-75, 2017. ,
, NCCN Clinical Practice Guidelines in Oncology, vol.84
Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer: FDG pet in the staging of bladder cancer, BJU International, vol.114, issue.3, pp.389-95, 2014. ,
Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer, Rev Esp Med Nucl E Imagen Mol, vol.32, issue.4, pp.214-235, 2013. ,
, SERMENT MEDICAL Version du Serment d'Hippocrate réactualisée et publiée dans le bulletin de l'Ordre National des Médecins, vol.4, 1996.
, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité
, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux
, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies
, Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité
, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences
, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire
, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés
, Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs
, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément
, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés
, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité
, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque